A pure domestic COVID-19 Vaccine No. 1, which was conducted by a domestic pharmaceutical company in charge of the entire process from development to production of raw materials and finished products, was released.

The MFDS approved SK Bioscience's SKY Covione on the 29th. It took 549 days (1 year and 6 months) from approval of the initial clinical trial to approval of the item.

SKY Covione was developed as GBP510 in May 2020 conduct non-clinical tests with the support of the Gates Foundation On December 31 of that year, phase 1 was obtained from the MFDS.

Phase 3 approval, the final stage of the clinical trial, took place on August 10 last year, and it was the first time t